// App-Quantinova.ai

TCT-649 : Safety and Efficacy of Overlapping Second Generation Drug-Eluting Stents Based Upon 2-year Clinical outcomes. Results from the Pooled Analysis of Five Trials from the International Global RESOLUTE Program

Researchers

Presenter

  • Vasim Farooq

Principal Investigators

  • Roberto Diletti

  • Hector Garcia-Garcia

  • Alan Yeung

  • Laura Mauri

  • Jorge Belardi

  • Sigmund Silber

  • Petr Widimsky

  • Martin Leon

  • Stephan Windecker

  • Ian Meredith

  • Franz-Josef Neumann

Medical Centers

  • University of Munich, Munich, Germany

  • Universitaets-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen, Germany

  • Shonan Kamakura General Hospital, Kanagawa, Japan

  • Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina

  • Charles Univ and VFN, Prague, Czech Republic

  • Thoraxcenter, Rotterdam, The Netherlands, Rotterdam, Netherlands

  • Harvard Medical School, Boston, Massachusetts

  • Deakin University, Melbourne, Australia

  • IBCSG and University Hospital, Berne, Switzerland

Locations

  • Czech Republic

  • Japan

  • Argentina

  • Netherlands

  • Germany

  • Switzerland

  • Australia

  • United States

Companies

  • Medtronic Plc

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • ZoMaxx

  • Paclitaxel

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved